Food and drugs occupied Latham & Watkins corporate lawyers last year. First, a team led by Valley partners Alan Mendelson and Mark Roeder advised OncoMed Pharmaceuticals on an IPO that raised $94 million. Then, Judith Hasko and Mendelson helped the company ink a strategic colloaboration deal with Celgene Corp. to jointly develop and commercialize OncoMed’s anti-cancer stem cell product candidates and small molecule anti-cancer therapeutics, a deal with a potential value of $3.3 billion. The OncoMed-Celgene deal includes an upfront payment to OncoMed of $155 million, the purchase by Celgene of some $22 million in newly issued shares of OncoMed stock and a series of milestone payments.
San Diego partner Cheston Larson and associate Matt Bush represented San Diego-based Conatus Pharmaceuticals Inc. in an IPO that raised $66 million to support Conatus’ focus on developing and commercializing novel medicines to treat liver disease. Latham also advised Conatus on previous venture financing rounds. All told, the firm had a hand in eight California biotech IPOs in 2013.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
